News stories about Avinger (NASDAQ:AVGR) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Avinger earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 46.0166786092779 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
Separately, Zacks Investment Research downgraded Avinger from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Avinger currently has a consensus rating of “Hold” and an average price target of $105.00.
Shares of Avinger (NASDAQ:AVGR) traded down $0.04 during mid-day trading on Friday, hitting $6.23. The company had a trading volume of 103,192 shares, compared to its average volume of 53,262. Avinger has a one year low of $6.02 and a one year high of $117.43. The stock has a market capitalization of $5.19, a P/E ratio of -0.07 and a beta of -0.23.
Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Thursday, November 9th. The medical device company reported ($17.20) earnings per share for the quarter.
In other Avinger news, insider John B. Ph D. Md Simpson sold 1,074,130 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $0.25, for a total transaction of $268,532.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman John B. Ph D. Md Simpson sold 454,584 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $0.27, for a total value of $122,737.68. The disclosure for this sale can be found here. Company insiders own 17.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Avinger (AVGR) Stock Price” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/04/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-avinger-avgr-stock-price.html.
Avinger Company Profile
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.